Skip to content
newsechoasia

newsechoasia

Press Releases, Companye Events, Business News in Asia

Menu
  • Home
  • SeaPRwire
  • ACN
  • JCN
  • EQS
  • Finance
  • Business
  • Instant
  • Contact

Tag: clinical

Posted onMarch 11, 2022

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting

TOKYO, Mar 11, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer’s disease…

Read More
Posted onMarch 4, 2022

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to…

Read More
Posted onMarch 2, 2022

Avance Clinical Announces New Office Opening in Sydney

SYDNEY, Mar 2, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened…

Read More
Posted onFebruary 9, 2022

Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report

SYDNEY, Feb 9, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been recognized as a top 10…

Read More
Posted onFebruary 7, 2022

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock…

Read More
Posted onFebruary 7, 2022

Football: Clinical Barcelona down Atletico 4-2 win at Camp Nou

Read More
Posted onJanuary 28, 2022

Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

Cambridge, MA, Jan 28, 2022 – (JCN Newswire via SEAPRWire.com) – Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the…

Read More
Posted onJanuary 19, 2022

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

TOKYO, Jan 19, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led…

Read More
Posted onJanuary 19, 2022

Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资

ADELAIDE, AUS, Jan 19, 2022 – (亚太商讯 via SEAPRWire.com) – Avance Clinical 是澳大利亚最大的国际生物技术高级合同研究组织 (CRO),已获得全球私…

Read More
Posted onJanuary 18, 2022

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has…

Read More
Posted onJanuary 12, 2022

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

HANGZHOU, CHINA, Jan 12, 2022 – (ACN Newswire via SEAPRWire.com) – On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report…

Read More
Posted onJanuary 5, 2022

B-cell lymphoma clinical trials now open on the TrialWire Platform

ADELAIDE, AUS, Jan 5, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) is pleased to announce new B-cell lymphoma clinical studies are now available on…

Read More
Posted onJanuary 5, 2022

Autism clinical trials now open on the TrialWire Platform

ADELAIDE, AUS, Jan 5, 2022 – (ACN Newswire via SEAPRWire.com) – TrialWire(TM) is pleased to announce new Autism (ASD) clinical studies are now available on…

Read More
Posted onDecember 24, 2021

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

TOKYO, Dec 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta)…

Read More
Posted onNovember 30, 2021

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical…

Read More
Posted onNovember 22, 2021

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Foster City, CA, Shanghai and Hangzhou, China, Nov 22, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics Inc., an innovative biopharmaceutical company committed to the…

Read More
Posted onNovember 12, 2021

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses…

Read More
Posted onNovember 12, 2021

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the…

Read More
Posted onNovember 9, 2021

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led…

Read More
Posted onNovember 2, 2021

How Singapore’s first graduate medical school uses experiential learning to build skills and confidence

A man with terminal cancer who has to be told he has only weeks left to live. A disoriented woman, unaware of her surroundings, keeps…

Read More

Posts navigation

Previous Page Page 1 Page 2 Page 3 Page 4 … Page 6 Next Page

目录导航

  • 首页
  • SeaPRwire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • 商业新闻
  • 财经新闻
  • 即时热闻
  • 联络我们
  • 关于我们
  • RSS

Singapore News

  • 凯西·伍德的最新选股 September 18, 2025
  • Dongwu Cement (00695.HK) Undergoes Major Transformation with Suzhou State Capital Takeover September 18, 2025
  • 值得关注的量子计算股票 September 18, 2025
  • 特朗普援引丘吉尔及“特殊关系”,正值英国言论自由受质疑日益增多 September 17, 2025
  • 西班牙首相因涉嫌对以色列发出核威胁引发众怒 September 17, 2025
  • 南美国家因柴油价格上涨爆发暴力抗议,全国宣布进入紧急状态 September 17, 2025
  • 值得关注的顶级AI股票 September 17, 2025
  • 香港董事学会的《施政报告》回应 经济虽在转型 机会大于挑战 September 17, 2025
  • GMG Launches First to Market Multi Language Global Graphene Enhanced Product Range for Distributors September 17, 2025
  • 克鲁兹抨击联合国对以色列的“种族灭绝”指控,推动追究责任 September 17, 2025
  • Casa Minerals Inc Announces Advanced Ground IP Survey at the Arsenault Project September 17, 2025
  • Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines September 17, 2025
  • Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches ‘Global Open Innovation’ for U.S. Startups September 17, 2025
  • Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation September 17, 2025
  • HKTDC welcomes 2025 Policy Address September 17, 2025

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • PostVN
  • VOASG
  • EventPH
© Copyright 2024 – NewsEchoAsia